(Q35753968)

English

Use of fluorescence in situ hybridization to predict response to bacillus Calmette-Guérin therapy for bladder cancer: results of a prospective trial

scientific article published on 15 January 2012

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

10 August 2017

Use of fluorescence in situ hybridization to predict response to bacillus Calmette-Guérin therapy for bladder cancer: results of a prospective trial (English)

1 reference

Europe PubMed Central

10 August 2017

1 reference

based on heuristic

inferred from title

author name string

Ashish M Kamat

1

1 reference

Europe PubMed Central

10 August 2017

Rian J Dickstein

2

1 reference

Europe PubMed Central

10 August 2017

Fabrizio Messetti

3

1 reference

Europe PubMed Central

10 August 2017

Roosevelt Anderson

4

1 reference

Europe PubMed Central

10 August 2017

Shanna M Pretzsch

5

1 reference

Europe PubMed Central

10 August 2017

Graciela Noguera Gonzalez

6

1 reference

Europe PubMed Central

10 August 2017

Ruth L Katz

7

1 reference

Europe PubMed Central

10 August 2017

Abha Khanna

8

1 reference

Europe PubMed Central

10 August 2017

Tanweer Zaidi

9

1 reference

Europe PubMed Central

10 August 2017

Xifeng Wu

10

1 reference

Europe PubMed Central

10 August 2017

H Barton Grossman

11

1 reference

Europe PubMed Central

10 August 2017

Colin P Dinney

12

1 reference

Europe PubMed Central

10 August 2017

language of work or name

0 references

publication date

15 January 2012

1 reference

Europe PubMed Central

10 August 2017

Journal of Urology

1 reference

Europe PubMed Central

10 August 2017

187

1 reference

Europe PubMed Central

10 August 2017

862-867

1 reference

Europe PubMed Central

10 August 2017

3

1 reference

Europe PubMed Central

10 August 2017

Fluorescence in situ hybridization for detecting urothelial carcinoma: a clinicopathologic study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3278506

2 October 2017

Cancer statistics, 2010

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3278506

2 October 2017

Clinical evaluation of a multi-target fluorescent in situ hybridization assay for detection of bladder cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3278506

2 October 2017

A multicolour fluorescence in situ hybridization test predicts recurrence in patients with high-risk superficial bladder tumours undergoing intravesical therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3278506

25 September 2018

Clinical utility of fluorescent in situ hybridization for the surveillance of bladder cancer patients treated with bacillus Calmette-Guérin therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3278506

25 September 2018

Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3278506

25 September 2018

Monitoring intravesical therapy for superficial bladder cancer using fluorescence in situ hybridization.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3278506

25 September 2018

Is bladder biopsy necessary at three or six months post BCG therapy?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3278506

25 September 2018

Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3278506

25 September 2018

Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3278506

25 September 2018

Multi-target fluorescence in situ hybridization in bladder washings for prediction of recurrent bladder cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/22245325

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A comparison of cytology and fluorescence in situ hybridization for the detection of urothelial carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/22245325

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Multiprobe FISH for enhanced detection of bladder cancer in voided urine specimens and bladder washings

1 reference

https://pubmed.ncbi.nlm.nih.gov/22245325

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Does early cystectomy improve the survival of patients with high risk superficial bladder tumors?

1 reference

https://pubmed.ncbi.nlm.nih.gov/22245325

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Immunotherapy for bladder cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/22245325

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

UroVysion multiprobe FISH in urinary cytology

1 reference

https://pubmed.ncbi.nlm.nih.gov/22245325

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Interim results from a national multicenter phase II trial of combination bacillus Calmette-Guerin plus interferon alfa-2b for superficial bladder cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/22245325

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Superficial bladder cancer: progression and recurrence

1 reference

https://pubmed.ncbi.nlm.nih.gov/22245325

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Is transurethral biopsy of the bladder necessary after 3 months to evaluate response to bacillus Calmette-Guerin therapy?

1 reference

https://pubmed.ncbi.nlm.nih.gov/22245325

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The prognostic value of cytology and fluorescence in situ hybridization in the follow-up of nonmuscle-invasive bladder cancer after intravesical Bacillus Calmette-Guérin therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/22245325

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1016/J.JURO.2011.10.144

1 reference

Europe PubMed Central

10 August 2017

1 reference

Europe PubMed Central

10 August 2017

1 reference

Europe PubMed Central

10 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35753968&oldid=1523751007"